Treatment with sorafenib in advanced thyroid cancer - a case report.

摘要: Papillary thyroid cancer (PTC) usually has a good prognosis. The treatment, including total thyroidectomy and complementary radioiodine (RAI) therapy, gives complete remission in 90% of patients. However, 10% subjects with metastatic disease, the prognosis is poor. In group patients disease progression no 131I uptake, searching for new therapeutic modalities before all tyrosine kinase inhibitors other antiangiogenic agents necessary. study presents case 55-year-old male advanced PTC /pT3mNxMo/ diagnosed 1993. Primary treatment by thyroidectomy and ablation led to remission. In 2000 local as well lymph node recurrence was successively treated surgery. 2006 an increasing serum thyroglobulin level noted single lung metastasis operated on. In 2007 foci CNS vertebral column uptake were stated. Further (bones, CNS, pterygoid muscle) was confirmed PET-CT. patient underwent neurosurgical metastasectomy twice palliative vertebra’s radiotherapy. Liver metastases 2009. Treatment doses thalidomide (up 800 mg/d) administered 3 months with tolerance; however, therapy withdrawn due progression. Next, sorafenib (800 given 16 weeks. Radiological examination performed after weeks stable whereas 2 months later, withdrawal to lack possibility, further observed. Metronomic chemotherapy Adriamycin instituted which gave disease stabilization 6 months. died disseminated pulmonary embolism. We present this document adverse effects brain DTC metastases. Sorafenib therapy was only short-term, but occurred time. (Pol J Endocrinol 2010; 61 (5): 492-496)